ongoing

Thrombotic complications are common in COVID-19 cases; the objective of ACT-COAG is to measure the effect of study treatments on coagulation biomarkers to identify the most promising therapies early and unravel mechanisms of thrombotic complications.

ACT COAG is a substudy of PHRI’s ACT COVID-19 research program.

PHRI is working in collaboration with scientists Jeffrey Weitz and Paul Kim at the Thrombosis and Atherosclerosis Research Institute (TaARI) in Hamilton, Canada, on the ACT COAG substudy.

Study Type

Observational

Study Design

Substudy

NO. of Countries

multi

NO. of Sites

multi

NO. of Participants

400

Study Period

2020 - 2021

Sponsor

PHRI

McMaster COVID-19 Research Fund

Hamilton Academic Health Sciences Organization (HAHSO)

Back To Top